Rezdiffra (resmetirom) — Topline data
in 2027
Baseline characteristics of patients from the OLE F4c cohort are similar to patients enrolled in the ongoing MAESTRO-NASH OUTCOMES trial which is expected to read out topline data in 2027.Source filing
MDGL biotech catalysts & pipeline
MADRIGAL PHARMACEUTICALS INC · Data as of 2026-10-27
Upcoming catalysts
Rezdiffra (resmetirom) — Clinical data readout
2028
We expect outcomes data from this trial in 2028.Source filing
Rezdiffra (resmetirom) — Conference presentation
Nov 5–Nov 9
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place Nov. 5-9 in Denver.Source filing